SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...


CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinson’s Disease, Alzheimer’s Disease and less common neurodegenerative disorders. The company is developing small molecule drugs targeting a novel mechanism in the brain to modify disease pathology, and alleviate disabling symptoms, such as cognition, executive function, and motor and autonomic dysfunction, all of which can severely impact quality of life.